Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

Interest in neurofilaments has risen sharply in recent years with recognition of their potential
as biomarkers of brain injury or neurodegeneration in CSF and blood. This is in the context …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …

Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative disease of the
central nervous system characterized by demyelination and axonal damage. Diagnosis and …

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis
(MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up …

Objective To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and
neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments …

Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple
sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels …